Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hormone therapy and raloxifene reduce the coagulation inhibitor potential.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis - 1 Jul 2007

Andresen Marianne S, Eilertsen Anette L, Abildgaard Ulrich, Sandset Per Morten

Abstract excerpt

The coagulation inhibitor potential (CIP) assay may detect major thrombophilia at a sensitivity of 100% and a specificity of 70-80%. Subnormal CIP might be associated with increased risk of thrombosis. This study compared the effect on CIP in plasma samples from postmenopausal women treated with four different regimens. Fibrin aggregation in plasma was monitored after activation with tissue factor. The effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Estrogen Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Replacement Therapy

Share to Factor V

Share to Fibrin

Share to Postmenopause

Share to Thrombophilia

Share to Venous Thromboembolism

Source

Identifiers

PMID: 17581320
DOI: 10.1097/MBC.0b013e32813a2de7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hormone therapy and raloxifene reduce the coagulation inhibitor potential.PMID 17581320Read ↗

Thrombosis risk with the use of hormonal contraception among women with thrombophilia: An updated systematic review.Semantic proximity Read ↗

Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy.Semantic proximity Read ↗

Integrating Pharmacokinetic, Pharmacogenomic, and Clinical Risk Data to Individualise Hormonal Contraception and Minimise Thrombotic Risk: A Translational Framework.Semantic proximity Read ↗

Should coagulation tests be used to determine which oral contraceptive users have an increased risk of thrombophlebitis?Semantic proximity Read ↗

Hormonal contraception, thrombosis and age.Semantic proximity Read ↗

Oral contraceptives and the risk of thrombosis and atherosclerosis.Semantic proximity Read ↗

Oral contraceptives, hormone therapy and cardiovascular risk.Semantic proximity Read ↗

Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study.Semantic proximity Read ↗

Ageing, oestrogen, platelets and thrombotic risk.Semantic proximity Read ↗

Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.Semantic proximity Read ↗

Plasma Fibrin Clot Properties Are Unfavorably Altered in Women following Venous Thromboembolism Associated with Combined Hormonal Contraception.Semantic proximity Read ↗

Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.